What does the future hold for immunotherapy in cancer? Journal Article
| Authors: | Naidoo, J.; Li, B. T.; Schindler, K.; Page, D. B. |
| Article Title: | What does the future hold for immunotherapy in cancer? |
| Keywords: | cancer survival; protein expression; overall survival; bevacizumab; fluorouracil; placebo; drug dose comparison; liver cell carcinoma; nonhuman; drug approval; bone metastasis; drug targeting; cancer radiotherapy; flow cytometry; outcome assessment; colorectal cancer; cytotoxic t lymphocyte antigen 4 antibody; dacarbazine; ipilimumab; ticilimumab; cancer immunotherapy; multiple cycle treatment; editorial; food and drug administration; kidney carcinoma; hodgkin disease; prostate cancer; regulatory t lymphocyte; immune response; folinic acid; cancer cell; malignant neoplastic disease; effector cell; cytotoxic t lymphocyte antigen 4; bladder carcinoma; oxaliplatin; chronic lymphatic leukemia; transitional cell carcinoma; t lymphocyte activation; lymphocyte count; head and neck carcinoma; inducible t cell costimulator; programmed death 1 ligand 1; programmed death 1 receptor; non small cell lung cancer; metastatic melanoma; tumor microenvironment; molecularly targeted therapy; melanoma vaccine; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); major histocompatibility antigen; dabrafenib; trametinib; nivolumab; pidilizumab; human; pembrolizumab; durvalumab; osimertinib; atezolizumab; avelumab |
| Journal Title: | Annals of Translational Medicine |
| Volume: | 4 |
| Issue: | 9 |
| ISSN: | 2305-5839 |
| Publisher: | AME Publishing Company |
| Date Published: | 2016-05-01 |
| Start Page: | 177 |
| Language: | English |
| DOI: | 10.21037/atm.2016.04.05 |
| PROVIDER: | scopus |
| PMCID: | PMC4876278 |
| PUBMED: | 27275490 |
| DOI/URL: | |
| Notes: | Editorial -- Export Date: 2 August 2016 -- Source: Scopus |
